The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
Mirati gets a combo coup
An adagrasib/Keytruda combo in front-line lung cancer looks promising, but patient numbers are small and Amgen looms large.
ASN 2021 – Glaxo’s daprodustat delivers
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
TCT 2021 – Medtronic and Edwards target hard-to-reach valves
Transcatheter technologies could be the future – but a distant one.
Esmo IO 2021 – Propel fails to propel Nektar
The focus now falls on first-line melanoma data with bempegaldesleukin plus Opdivo, due in early 2022.
